FDA should be required to better explain the factors used in its cost-benefit analysis of the expected effects of the ephedrine proposed rule, the General Accounting Office states in a report on the rule released Aug. 4.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.
As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.
